4D Molecular Therapeutics (FDMT) EBIT Growth (3y) (2023 - 2026)
4D Molecular Therapeutics (FDMT) EBIT Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 38.78% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 13.47% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -12.10% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 79.65% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 691.54 Mn | 300.64 Mn | - | -34.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.72% |
| Dec 31, 2025 | 35.94% |
| Sep 30, 2025 | -32.18% |
| Jun 30, 2025 | -27.89% |
| Mar 31, 2025 | -26.65% |
| Dec 31, 2024 | -31.35% |
| Sep 30, 2024 | -31.16% |
| Jun 30, 2024 | -77.47% |
| Mar 31, 2024 | -32.72% |
| Dec 31, 2023 | -21.53% |
| Sep 30, 2023 | -21.37% |
| Jun 30, 2023 | -28.49% |
| Mar 31, 2023 | -31.38% |